{"id":"W2947840610","doi":"10.1200/jco.2019.37.15_suppl.4005","title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) <i>(</i>Alliance A021202<i>)</i>.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Pazopanib; Internal medicine; Hazard ratio; Regorafenib; Neuroendocrine tumors; Gastroenterology; Placebo; Randomization; Progression-free survival; Randomized controlled trial; Urology; Cancer; Confidence interval; Chemotherapy; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002990123,0.0002551226,0.0039167,0.0002139199,0.00003123779,0.000007552507,0.0003154443,0.00007211335,0.000155626],"category_scores_gemma":[0.01360448,0.000159047,0.0005707844,0.0003747586,0.0007418518,0.0002607004,0.0001288317,0.001750981,0.00001053379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002178694,"about_ca_system_score_gemma":0.002317811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001230638,"about_ca_topic_score_gemma":0.00001957663,"domain_scores_codex":[0.9934555,0.001317469,0.003162075,0.0003915585,0.001180169,0.00049321],"domain_scores_gemma":[0.9893184,0.005441636,0.003233785,0.0003340585,0.001234255,0.0004378984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9016483,0.009959564,0.08149265,0.0000718885,0.0003539026,0.00243918,0.00006673799,0.00001734322,0.00004527287,0.00005933226,0.0002172221,0.003628592],"study_design_scores_gemma":[0.8020923,0.1822305,0.01359849,0.0002720387,0.0002237075,0.00008523467,0.00008925888,0.00002696034,0.0004030979,0.000109422,0.0007562648,0.0001127694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904234,0.0002354163,0.000004132182,0.001252734,0.001273115,0.004835437,0.000008477213,0.000009428759,0.001957819],"genre_scores_gemma":[0.9973975,0.0001348962,0.001396892,0.0001898437,0.0005350338,0.00007116001,0.000004339941,0.00003314848,0.0002371518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1722709,"threshold_uncertainty_score":0.9947044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05478446337088199,"score_gpt":0.4539388293389862,"score_spread":0.3991543659681042,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}